Lehigh Valley Hospital Negotiating Risk Contracts With Manufacturers
Executive Summary
Lehigh Valley Hospital is in negotiations with two manufacturers for contracts that would include guarantees related to reduced lengths of stay
You may also be interested in...
ReoPro Post-Approval Trials Have Cost $250 Mil. Including J&J Stent Work
Centocor has spent about $250 mil. on post-approval trials since 1995 to demonstrate the efficacy of ReoPro in combination with coronary stents and to generate outcomes data for the antiplatelet monoclonal, Centocor CEO David Holveck reported at the recent Wharton New Ventures in Health Care Conference.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials